Peptide Policy Watch

Is BPC-157 FDA approved? Four official lists, four different answers

By · Published

Four pinned index cards about BPC-157 with stamped answers: FDA-approved drug, no; on FDA's Category 2 risk list, no longer; bulk compounding by 503A pharmacies, not settled; allowed in sport under WADA rules, no.

Someone at the gym swears BPC-157 "got FDA approval this summer." Someone else says it was "banned, then unbanned." You search it and find headlines about a vote, a list, a White House review. Which is it?

Short answer: no, BPC-157 is not an FDA-approved drug. The longer answer is more interesting, because the confusion comes from four separate lists, each answering a different question.

Facts are as of October 26, 2026. Sources, with retrieval dates, are at the bottom.

Where BPC-157 stands, list by list
The questionAnswerWhat the record shows
Is it an FDA-approved drug?NoThere is no FDA approval and no FDA-approved label. A 2025 review describes it as lacking FDA approval. [V]
Is it on FDA's Category 2 risk list?No longerListed since April 2026 under nominations that were withdrawn; FDA's risk text stays on the page. [V]
Can state-licensed pharmacies compound it from bulk?Not settledFDA's briefing proposed against adding it; an advisory panel reportedly voted to add it; FDA has not announced a decision. [V] [S]
Is it allowed in sport?NoNamed in the non-approved substances class (S0) of WADA's lists. [S]

List 1: FDA approval

Approval is the big one. It means a company filed an application, FDA reviewed the clinical data, and the drug got a label that spells out its approved uses and warnings. BPC-157 has none of that. A 2025 systematic review in HSS Journal describes it as a substance without FDA approval. [V]

List 2: Category 2, the "significant safety risks" page

This is where the "banned" talk started. Category 2An interim FDA group of nominated bulk ingredients that FDA has flagged for possible significant safety risks while its review continues. is FDA's list of bulk ingredients nominated for compounding that the agency flagged as possibly presenting significant safety risks. BPC-157 was on it. FDA's page (current as of April 22, 2026) now puts BPC-157 in a section for nominations that were withdrawn. [V]

Leaving that list is not a green light. The page still carries FDA's concerns: possible immune reactions for some routes, peptide-related impurities, and little or no safety information. FDA wrote that it "lacks sufficient information to know whether the drug would cause harm when administered to humans." [V] We also searched FDA's 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. category list (updated May 14, 2026) and did not find BPC-157 in any of its categories. [V]

List 3: the 503A bulks list

State-licensed pharmacies (503A pharmacies) can compound from bulk ingredients on a short official list, among other routes. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee discussed whether to add BPC-157. The use FDA evaluated was ulcerative colitis. [V] FDA's briefing laid out a proposal to keep all seven peptides on the agenda off the list. [V]

The vote is where things get murky. AJMC reported that the committee recommended BPC-157 by 8 to 6 with one abstention, overriding FDA staff. [S] As of today, FDA's meeting page (current as of August 6, 2026) lists the briefing documents, agenda and roster, but no minutes or vote summary that we could find. [V]

Advisory committees make non-binding recommendations to the FDA [V]

FDA, July 23-24, 2026 advisory committee page

FDA's page goes on to say the agency generally follows them but isn't legally bound to. So a panel vote is not a decision, and it is certainly not an approval. [V]

Then there's the White House piece. OMB's regulatory review site lists an HHS/FDA item called "Interim Access Policy for Compounding Using Certain Peptides," received October 14, 2026 and still pending as of our check today. [V] Its text isn't public, so we can't say which peptides it covers or what it would allow.

List 4: sport

Athletes face a separate rulebook. BPC-157 is named in the S0 class of WADA's Prohibited List, the bucket for substances with no government approval for human therapeutic use. [S] Our WADA explainer walks through how that list works.

What the human research looks like

None of the lists above measures whether BPC-157 works. That's a research question. A 2025 review counted one human study among 36 it included. A 2026 review counted three and rated the overall certainty of evidence "very low." [V] Our evidence ladder walks through what those studies were.

What people get wrong

Claim

"The FDA panel voted yes, so BPC-157 is approved now."

What research shows

  • None (a question about regulatory status)

The July 2026 meeting was about the 503A bulks list for compounding, not drug approval. FDA describes committee votes as non-binding, and we found no FDA decision or minutes posted. [V] The reported vote count comes from news coverage. [S]

What is unknown

What FDA will decide on the bulks list, and what the pending interim access policy says.

This card describes the kind of research that exists.

The opposite mistake happens too. "Off Category 2" sometimes gets read as "cleared as safe." FDA's own page says the agency doesn't have enough information to know whether it causes harm in people. Not reviewed is not the same as proven safe, or proven unsafe. [V]

Why it matters

When a friend, a clinic menu or a forum post says "FDA approved," it helps to know there are at least four separate things they might really mean, and only one of them is approval. Each list is public, and each has a date on it.

Questions to bring to a clinician or pharmacist

  1. Is the product you're describing an FDA-approved drug, or something else?
  2. If it's compounded, what rule allows the pharmacy to use this ingredient right now?
  3. What human studies support the use being suggested, and how many people were in them?
  4. If I compete in a tested sport, have I checked with my anti-doping organization?

What to watch next

Dates and decisions we're tracking

  1. No date setMinutes or a vote summary from the July 23–24 advisory meeting on FDA's site [V]
  2. No date setFDA's decision on adding BPC-157 to the 503A bulks list [V]
  3. Pending since Oct. 14, 2026White House review of the interim access policy for certain peptides [V]
  4. Before end of Feb. 2027FDA's planned advisory consult on GHK-Cu, one of five substances on the next meeting's agenda [V]

The full sequence is in our regulation timeline, and the categories are explained in our Category 1 and 2 explainer.

Sources (retrieved October 26, 2026 unless noted)

  1. FDA, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (Category 2 page), content current as of 04/22/2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. FDA, 503A bulk drug substances category list (PDF), updated May 14, 2026, including FDA's plan to consult the committee on GHK-Cu before the end of February 2027 [V] — https://www.fda.gov/media/94155/download
  3. FDA, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee," content current as of 08/06/2026 [V] — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  4. FDA, briefing document introduction for the July 23–24, 2026 meeting (retrieved October 25, 2026) [V] — https://www.fda.gov/media/193342/download
  5. AJMC (secondary), "FDA panel backs 6 peptides for compounding," July 31, 2026 (retrieved October 25, 2026) [S] — https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  6. OMB/OIRA, pending EO 12866 regulatory review, RIN 0910-ZD94 [V] — https://www.reginfo.gov/public/do/eoDetails?rrid=1568964
  7. Vasireddi N, et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025 (abstract on PubMed, retrieved October 25, 2026) [V] — https://pubmed.ncbi.nlm.nih.gov/40756949/
  8. Poolton JT, Minett J, Kazmi A, "Human evidence for BPC-157 in orthopaedic and regenerative medicine," Acta Orthopaedica Belgica 92(3), 2026 (abstract, retrieved October 25, 2026) [V] — https://doi.org/10.52628/92.3.15837
  9. WADA, 2027 Prohibited List text, read from a copy hosted by FIS (retrieved October 25, 2026) [S] — https://assets.fis-ski.com/f/252177/x/4526d29144/2027list_en_final_clean_26_august_2026_2.pdf
  10. FDA, Pharmacy Compounding Advisory Committee meeting page for the next meeting (date not yet set; five substances on the agenda) [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee

Spot a mistake? See how we source and our corrections policy.